Dharmacon

Dharmacon is a biotechnology brand focused on tools for manipulating and studying gene function. The business began in 1995 as Dharmacon Research, founded by Stephen Scaringe to develop and commercialize a chemistry for RNA oligonucleotide synthesis. Its early work centered on 2'-ACE RNA technology and on applications that depended on synthetic RNA oligonucleotides. Rather than operating primarily as a therapeutics company, Dharmacon developed products and supporting technologies for academic, pharmaceutical, biotechnology, and other life-science researchers. The emergence of RNA interference, or RNAi, in the late 1990s created a major opportunity for the company. RNAi uses small interfering RNA molecules to reduce the expression of selected genes, making it useful for investigating gene function and for exploring possible therapeutic mechanisms. Dharmacon's synthesis chemistry, RNA biology, and bioinformatics capabilities enabled it to supply siRNA and related reagents for gene knockdown experiments. The company became associated with comprehensive RNAi research workflows, including reagent design and products intended to improve the specificity, potency, and reproducibility of gene-silencing studies. In November 2002, Dharmacon Research formally changed its name to Dharmacon, Inc. The change reflected the company's move beyond an early research orientation toward broader commercial solutions for RNA oligonucleotide-dependent applications. In March 2004, Fisher Scientific International acquired Dharmacon as a wholly owned subsidiary. Fisher later merged with Thermo Electron in 2006, creating Thermo Fisher Scientific and placing Dharmacon within a much larger laboratory-supplies and life-science-products organization. Dharmacon subsequently expanded beyond conventional RNA interference products. When Thermo Fisher agreed to acquire Life Technologies, European competition authorities required divestitures involving several businesses, including Thermo Fisher's Dharmacon gene-modulation operation. GE Healthcare agreed in early 2014 to acquire the Dharmacon business, along with other divested assets, for a reported total transaction value of US$1.05 billion. Under GE Healthcare, the brand extended its gene-modulation portfolio into CRISPR-Cas9 genome engineering. In October 2014, GE Healthcare Dharmacon introduced Edit-R products, its first CRISPR-Cas9 product family. In 2015, it added pre-designed synthetic crRNA and lentiviral single-guide RNA products supported by an algorithm designed for genome-wide targeting across human, mouse, and rat research systems. In July 2017, Horizon Discovery agreed to acquire Dharmacon from GE Healthcare for total consideration of US$85 million. The transaction was intended to combine Dharmacon's gene-modulation reagents with Horizon's gene-editing products and engineered cell-line capabilities. Across its ownership changes, the brand's core role remained that of a research-enablement business: it provides reagents, design resources, and gene-modulation technologies that allow scientists to perturb genes and analyze resulting cellular or molecular effects. The available reference material does not establish a current standalone corporate structure, headquarters, executive team, or present ownership, so those details are left unspecified.

Dharmacon was founded in 1995 by Stephen Scaringe as Dharmacon Research. Its initial objective was to develop and commercialize 2'-ACE RNA technology as a platform for RNA oligonucleotide synthesis. The company also sought to advance applications that relied on synthetic RNA molecules, establishing an early foundation in RNA chemistry and oligonucleotide-based research tools. The rise of RNA interference in the late 1990s redirected the commercial opportunity toward gene silencing. RNAi enabled researchers to reduce expression of selected genes with small interfering RNA, creating a widely adopted method for functional genomics and early-stage therapeutic research. Dharmacon supplied products for this emerging field and developed capabilities spanning siRNA design, RNA biology, synthesis chemistry, and bioinformatics. These capabilities allowed it to offer more than individual oligonucleotides: the brand became a source of integrated gene-knockdown tools for scientists studying gene function and evaluating RNAi-based mechanisms. In November 2002, the business changed its legal name from Dharmacon Research, Inc. to Dharmacon, Inc. The rebranding signaled that the company had progressed from an R&D-centered organization into a commercial provider of RNA oligonucleotide solutions. In March 2004, Fisher Scientific International acquired the company and operated it as a wholly owned subsidiary. Fisher Scientific later merged with Thermo Electron in November 2006, forming Thermo Fisher Scientific. Dharmacon consequently became part of a large global laboratory-products group while retaining its specialist identity in gene modulation. A major ownership transition followed Thermo Fisher's planned acquisition of Life Technologies. In 2013, the European Commission conditionally approved the transaction, requiring divestiture of certain assets to address competition concerns. The divestitures included Thermo Fisher's Dharmacon gene-modulation business, along with cell-culture and magnetic-bead operations. In early 2014, GE Healthcare agreed to acquire the relevant businesses for total consideration reported at US$1.05 billion. GE Healthcare viewed Dharmacon as complementary to its drug-discovery research technologies. Under GE Healthcare, Dharmacon broadened its scope from RNA interference into genome editing. In 2014, GE Healthcare reached a licensing agreement with the Broad Institute of MIT and Harvard concerning CRISPR-Cas9 intellectual property. The arrangement enabled GE Healthcare to incorporate the licensed technologies and develop additional gene-editing reagents. In October 2014, GE Healthcare Dharmacon launched the Edit-R product family, its first CRISPR-Cas9 genome-engineering offering. The launch connected Dharmacon's established expertise in gene modulation with the rapidly developing CRISPR research market. In July 2015, the company added synthetic crRNA and lentiviral sgRNA products pre-designed for targets across human, mouse, and rat genomes. These products used a functionally validated algorithm intended to support systematic targeting and reduce the design burden for researchers. The expansion illustrated Dharmacon's movement toward broader, scalable gene-editing workflows rather than a narrow focus on standalone siRNA reagents. In July 2017, UK-based Horizon Discovery agreed to acquire Dharmacon from GE Healthcare for total consideration of US$85 million. Horizon described the transaction as complementary to its gene-editing products and engineered cell-line portfolio. The available reference material does not provide enough information to document later corporate ownership, current headquarters, current executives, or present product availability with confidence. Dharmacon is therefore best characterized on the supplied evidence as a specialist gene-modulation and genome-engineering brand whose historical development tracks the expansion of RNA synthesis, RNAi, and CRISPR research technologies.

• 2017

  Horizon Discovery agrees to acquire Dharmacon

  [1]Dharmaconen.wikipedia.org

  Horizon Discovery agreed to buy Dharmacon from GE Healthcare for total consideration of US$85 million.

• 2015

  Pre-designed CRISPR guide products expand the portfolio

  [1]Dharmaconen.wikipedia.org

  Dharmacon launched synthetic crRNA and lentiviral sgRNA products designed for genome-wide research targeting in human, mouse, and rat systems.

• 2014

  GE Healthcare acquires the divested Dharmacon business

  [1]Dharmaconen.wikipedia.org

  GE Healthcare acquired Dharmacon and other divested businesses in a transaction associated with the regulatory approval of Thermo Fisher's Life Technologies acquisition.

• 2014

  Edit-R CRISPR-Cas9 products launch

  [1]Dharmaconen.wikipedia.org

  GE Healthcare Dharmacon entered the CRISPR-Cas9 research market with its Edit-R genome-engineering product family.

• 2006

  Fisher Scientific and Thermo Electron merge

  [1]Dharmaconen.wikipedia.org

  The merger created Thermo Fisher Scientific, bringing Dharmacon into the combined life-science and laboratory-products group.

• 2004

  Fisher Scientific acquisition

  [1]Dharmaconen.wikipedia.org

  Dharmacon became a wholly owned subsidiary of Fisher Scientific International.

• 2002

  Corporate name changes to Dharmacon, Inc.

  [1]Dharmaconen.wikipedia.org

  The company changed its name as it expanded from research and development into commercial RNA oligonucleotide solutions.

• 1995

  Dharmacon Research is founded

  [1]Dharmaconen.wikipedia.org

  Stephen Scaringe founded Dharmacon Research to develop and commercialize RNA oligonucleotide synthesis technology, initially emphasizing 2'-ACE RNA chemistry.

Research-focused gene-function and gene-modulation tools, combining RNA synthesis chemistry, RNA biology, bioinformatics, RNA interference, and genome-editing reagents.

• RNA interference reagents

  siRNA

  Small interfering RNA reagents used to reduce expression of selected genes. Dharmacon's expertise in RNA biology, synthesis chemistry, and bioinformatics supported products intended for gene-function studies, RNAi mechanism research, and exploration of RNA-based biotherapeutic concepts.

• RNA interference reagents

  shRNA

  Short hairpin RNA tools used for gene knockdown research. The supplied reference identifies shRNA as part of Dharmacon's typical product range, but does not provide detailed launch history or specific product specifications.

• CRISPR-Cas9 genome-engineering products · 2014

  Edit-R

  Dharmacon's first CRISPR-Cas9 genome-engineering product family, launched by GE Healthcare Dharmacon in October 2014. Edit-R extended the brand from RNA interference into targeted genome editing and provided reagents for researchers using CRISPR-Cas9 systems.

• CRISPR guide RNA reagents · 2015

  Synthetic crRNA

  Synthetic CRISPR RNA products introduced in 2015. Dharmacon described these as pre-designed with a functionally validated algorithm for targets across human, mouse, and rat genomes, supporting systematic gene-editing experiments.

• Viral CRISPR guide RNA reagents · 2015

  Lentiviral sgRNA

  Pre-designed lentiviral single-guide RNA products launched alongside synthetic crRNA products in 2015. They were intended to support CRISPR-Cas9 targeting across human, mouse, and rat research genomes using a validated design approach.

• 2017

  Sale of Dharmacon to Horizon DiscoveryM&A

  Background

  Horizon Discovery sought to complement its gene-editing products and engineered cell-line portfolio with Dharmacon's gene-modulation reagents.

  Action taken

  Horizon Discovery agreed to acquire Dharmacon from GE Healthcare.

  Aftermath

  Dharmacon joined Horizon Discovery's gene-editing and engineered-cell technology portfolio.

  Total acquisition consideration. US$85 million (Agreement announced in July 2017)

  Source

• 2015

  Expand pre-designed CRISPR guide offeringsProduct launch

  Background

  Researchers using genome-editing systems needed scalable guide-design and reagent options across commonly used model-organism genomes.

  Action taken

  Dharmacon launched pre-designed synthetic crRNA and lentiviral sgRNA products using a functionally validated targeting algorithm for human, mouse, and rat genomes.

  Aftermath

  The product expansion strengthened Dharmacon's position as a provider of ready-to-use gene-editing research reagents.

  Source

• 2014

  Divestiture of Dharmacon to GE HealthcareM&A

  Background

  Regulatory review of Thermo Fisher Scientific's planned acquisition of Life Technologies required divestiture of certain businesses, including the Dharmacon gene-modulation operation.

  Action taken

  GE Healthcare agreed to acquire Dharmacon and other businesses from Thermo Fisher for total consideration of US$1.05 billion.

  Aftermath

  Dharmacon became part of GE Healthcare's drug-discovery research technology portfolio.

  Total transaction consideration for Dharmacon and other divested businesses. US$1.05 billion (Agreement announced in early 2014)

  Source

• 2014

  Enter the CRISPR-Cas9 market with Edit-RProduct launch

  Background

  GE Healthcare had obtained access to CRISPR-Cas9 intellectual property through a licensing agreement with the Broad Institute of MIT and Harvard.

  Action taken

  GE Healthcare Dharmacon launched the Edit-R line of CRISPR-Cas9 genome-engineering products.

  Aftermath

  The launch broadened Dharmacon's gene-modulation portfolio from RNA interference into genome editing.

  Source

• 2002

  Adopt a commercial Dharmacon identityStrategy

  Background

  Dharmacon Research had expanded beyond its original research and development focus into commercial RNA oligonucleotide applications and technology solutions.

  Action taken

  The company changed its name to Dharmacon, Inc.

  Aftermath

  The name change formalized the brand's position as a commercial provider of RNA research tools.

  Source

1. 1Dharmaconen.wikipedia.org